HLS Therapeutics (TSX:HLS) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 11, 2026)


TSX:HLS HLS Therapeutics Inc TSX:HLS
67 GF Score
Price C$4.31
GF Value C$4.50
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics 5-Year Yield-on-Cost %?

HLS Therapeutics TSX:HLS +0.70% 67 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates TSX:HLS with a GF Score™ of 67/100 and a GF Value™ of C$4.50 (Fairly Valued). The stock has 4 warning signs investors should review. Among 516 Drug Manufacturers companies, HLS Therapeutics ranks worse than 193798.26% on this metric.

HLS Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for HLS Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, HLS Therapeutics's highest Yield on Cost was 4.84. The lowest was 0.00. And the median was 1.27.


TSX:HLS's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.24
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

HLS Therapeutics  (TSX:HLS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


HLS Therapeutics 5-Year Yield-on-Cost % Related Terms


TSX:HLS vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's 5-Year Yield-on-Cost % falls into.


TSX:HLS
67GF Score
HLS Therapeutics Inc TSX:HLS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of HLS Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
HLS Therapeutics (TSX:HLS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on HLS Therapeutics and its competitors. According to the industry distribution chart, HLS Therapeutics ranks #999999 out of 516 companies in the Drug Manufacturers industry.
Is HLS Therapeutics' 5-Year Yield-on-Cost % too high?
HLS Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, HLS Therapeutics ranks #999999 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, HLS Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #999999 out of 516 companies for 5-Year Yield-on-Cost %. This places HLS Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.24, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.50, compared to a current price of C$4.31 — trading 4.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. HLS Therapeutics' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.31 is trading 4.2% below its estimated GF Value™ of C$4.50. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: C$4.50 vs. price of C$4.31 (4.2% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
67GF Score

Get the complete analysis for TSX:HLS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.31
Price
C$4.50
GF Value